Esophageal Cancer
Advertisement
"PD-L1 inhibitors have significantly changed oncology [but] only about 30% of patients with cancer benefit from the drugs."
Dr. Andrew Hertler explains the FDA’s decision to narrow approvals for PD-1 inhibitors for stomach and esophageal cancers
Dr. Hertler breaks down the FDA’s restricting PD-1 inhibitor drugs for PD-L1-negative stomach and esophageal cancers
Researchers selected representative groups for individuals with more than a 5% risk of developing BE or EC
Individuals living in lower-income areas experience disproportionately higher rates of late-stage diagnoses and mortality.
Studies show that obesity is a risk factor for both Barrett's esophagus and esophageal cancer.
studies have identified important long-term risks of esophageal cancer, including tobacco, alcohol, and reflux esophagitis
Despite mounting evidence that no level of alcohol consumption is safe many people are unaware of the risks.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.